Tag:
Diamyd
Latest Headlines
Latest Headlines
Diamyd ends late-stage study of diabetes-prevention drug
Diamyd Medical has discontinued a late-stage study of a vaccine designed to prevent people at risk of Type 1 diabetes from developing the disease. The developer ended a European study last month
J&J dumps $625M diabetes drug pact with Diamyd
Just weeks after reporting the failure of its late-stage study of a Type 1 diabetes treatment, Diamyd Medical has announced that J&J's Ortho-McNeil has handed back the rights to the drug. And the
Diamyd to divide operations
Sweden's Diamyd Medical says it is dividing its operations into two parts: diabetes and pain. Elisabeth Lindner, president and CEO of Diamyd, said the move will come during the 2010/2011 fiscal year.
Ortho-McNeil inks twin diabetes pacts totaling $1B
Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals has nailed down commercialization rights to Diamyd Medical's late-stage Type 1 diabetes vaccine. OMJ and Sweden's Diamyd will
